ABSTRACT
PURPOSE: Two allosteric modulators of the group I metabotropic glutamate receptors (mGluR1 and mGluR5) were evaluated as positron emission tomography (PET) radioligands for mGluR1. METHODS: LY2428703, a full mGluR1 antagonist (IC(50) 8.9 nM) and partial mGluR5 antagonist (IC(50) 118 nM), and LSN2606428, a full mGluR1 and mGluR5 antagonist (IC(50) 35.3 nM and 10.2 nM, respectively) were successfully labeled with (11)C and evaluated as radioligands for mGluR1. The pharmacology of LY2428703 was comprehensively assessed in vitro and in vivo, and its biodistribution was investigated by liquid chromatography-mass spectrometry/mass spectrometry, and by PET imaging in the rat. In contrast, LSN2606428 was only evaluated in vitro; further evaluation was stopped due to its unfavorable pharmacological properties and binding affinity. RESULTS: (11)C-LY2428703 showed promising characteristics, including: (1) high potency for binding to human mGluR1 (IC(50) 8.9 nM) with no significant affinity for other human mGlu receptors (mGluR2 through mGluR8); (2) binding to brain displaceable by administration of an mGluR1 antagonist; (3) only one major radiometabolite in both plasma and brain, with a negligible brain concentration (with 3.5 % of the total radioactivity in cerebellum) and no receptor affinity; (4) a large specific and displaceable signal in the mGluR1-rich cerebellum with no significant in vivo affinity for mGluR5, as shown by PET studies in rats; and (5) lack of substrate behavior for efflux transporters at the blood-brain barrier, as shown by PET studies conducted in wild-type and knockout mice. CONCLUSION: (11)C-LY2428703, a new PET radioligand for mGluR1 quantification, displayed promising characteristics both in vitro and in vivo in rodents.
Subject(s)
Brain/pathology , Carbon Isotopes/pharmacology , Positron-Emission Tomography/methods , Receptors, Metabotropic Glutamate/metabolism , Allosteric Site , Animals , Blood-Brain Barrier , Chromatography, Liquid/methods , Humans , In Vitro Techniques , Inhibitory Concentration 50 , Ligands , Male , Mice , Mice, Knockout , Models, Chemical , Rats , Spectrometry, Mass, Electrospray Ionization/methods , Tandem Mass Spectrometry/methodsABSTRACT
Co-speech hand gestures influence language comprehension. The present experiment explored what part of the visual processing system is optimized for processing these gestures. Participants viewed short video clips of speech and gestures (e.g., a person saying "chop" or "twist" while making a chopping gesture) and had to determine whether the two modalities were congruent or incongruent. Gesture videos were designed to stimulate the parvocellular or magnocellular visual pathways by filtering out low or high spatial frequencies (HSF versus LSF) at two levels of degradation severity (moderate and severe). Participants were less accurate and slower at processing gesture and speech at severe versus moderate levels of degradation. In addition, they were slower for LSF versus HSF stimuli, and this difference was most pronounced in the severely degraded condition. However, exploratory item analyses showed that the HSF advantage was modulated by the range of motion and amount of motion energy in each video. The results suggest that hand gestures exploit a wide range of spatial frequencies, and depending on what frequencies carry the most motion energy, parvocellular or magnocellular visual pathways are maximized to quickly and optimally extract meaning.
Subject(s)
Gestures , Speech , Visual Perception , Female , Humans , Male , Movement , Photic Stimulation , Range of Motion, Articular , Reaction Time , Semantics , Videotape RecordingABSTRACT
A known chemotype of H(3) receptor ligand was explored for development of a radioligand for imaging brain histamine subtype 3 (H(3)) receptors in vivo with positron emission tomography (PET), namely nonimidazole 2-aminoethylbenzofurans, represented by the compound (R)-(2-(2-(2-methylpyrrolidin-1-yl)ethyl)benzofuran-5-yl)(4-fluorophenyl)methanone (9). Compound 9 was labeled with fluorine-18 (t(1/2) = 109.7 min) in high specific activity by treating the prepared nitro analogue (12) with cyclotron-produced [(18)F]fluoride ion. [(18)F]9 was studied with PET in mouse and in monkey after intravenous injection. [(18)F]9 showed favorable properties as a candidate PET radioligand, including moderately high brain uptake with a high proportion of H(3) receptor-specific signal in the absence of radiodefluorination. The nitro compound 12 was found to have even higher H(3) receptor affinity, indicating the potential of this chemotype for the development of further promising PET radioligands.
